On June 5, Lupin shares increased nearly 2% and touched a 52-week high of Rs 830.30 in early morning trade amid the launching of Darunavir tablets.

On June 3, Lupin declared the unveiling of 600 mg and 800 mg of Darunavir Tablets to market a generic like Prezista Tablets of Janssen Products, LP.

Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had projected yearly sales of $308 million in the United States.

Recently, Lupin’s wholly owned subsidiary Novel Laboratories Inc, grounded in Somerset, New Jersey, received sanction from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Claim for Diazepam Rectal Gel, 10 mg and 20 mg. Also, the Rectal Delivery System, a generic equivalent of Diastat AcuDialTM Rectal Delivery System, 10 mg and 20 mg, of Bausch Health US, LLC, was issued.

In May 2023, the firm’s Canada subsidiary acknowledged approval from Health Canada to market a generic form of Spiriva, receiving USFDA approval for Obeticholic Acid Tablets. It also declared a tactical collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar established for Cetuximab.

A combined net profit of Rs 236 crore for the January to March quarter was reported against a net loss of Rs 518 crore in the last year.

The top line rose 12.1% YoY to Rs 4,330.3 crore in the fourth quarter. Its EBIDTA margin expanded by 690 bps yearly to 14.2% from 7.3% in Q4FY22.

At 9:25 am, Lupin was trading at Rs 822.60, up Rs 5.45, or 0.67% on the BSE.